XNASXBIT
Market cap129mUSD
Jan 07, Last price
4.26USD
1D
-4.91%
1Q
-39.83%
Jan 2017
-57.91%
IPO
-81.24%
Name
XBiotech Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-3.20%
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-25m
L-25.36%
CFO
-19m
L+26.32%
Dividend
Jul 15, 20212.5 USD/sh
Earnings
Mar 13, 2025
Profile
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 4,010 -78.20% | ||||||||
Cost of revenue | 39,254 | 38,500 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (39,254) | (34,490) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 244 | (688) | |||||||
Tax Rate | |||||||||
NOPAT | (39,498) | (33,802) | |||||||
Net income | (24,557) -25.36% | (32,900) 88.93% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 5 | ||||||||
BB yield | 0.00% | ||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,669 | 1,576 | |||||||
Net debt | (200,023) | (217,478) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (18,725) | (14,824) | |||||||
CAPEX | (362) | (585) | |||||||
Cash from investing activities | 61,497 | (63,892) | |||||||
Cash from financing activities | (9) | ||||||||
FCF | (38,135) | (25,320) | |||||||
| Balance | |||||||||
Cash | 200,023 | 217,478 | |||||||
Long term investments | |||||||||
Excess cash | 200,023 | 217,278 | |||||||
Stockholders' equity | 218,846 | 240,402 | |||||||
Invested Capital | 20,492 | 24,646 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 30,438 | 30,439 | |||||||
Price | 4.00 13.96% | 3.51 -68.46% | |||||||
Market cap | 121,754 13.96% | 106,842 -68.05% | |||||||
EV | (78,269) | (110,636) | |||||||
EBITDA | (37,510) | (31,876) | |||||||
EV/EBITDA | 2.09 | 3.47 | |||||||
Interest | 902 | ||||||||
Interest/NOPBT | |||||||||